Circassia Pharmaceuticals logo

CIR - Circassia Pharmaceuticals Share Price

24p 0.2  0.8%

Last Trade - 8:33am

Sector
Healthcare
Size
Small Cap
Market Cap £89.3m
Enterprise Value £84.5m
Revenue £47.8m
Position in Universe 996th / 1834
Bullish
Bearish
Unlock CIR Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CIR Revenue Unlock CIR Revenue

Net Income

CIR Net Income Unlock CIR Revenue

Normalised EPS

CIR Normalised EPS Unlock CIR Revenue

PE Ratio Range

CIR PE Ratio Range Unlock CIR Revenue

Dividend Yield Range

CIR Dividend Yield Range Unlock CIR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CIR EPS Forecasts Unlock CIR Revenue
Profile Summary

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated May 19, 2006
Public Since March 13, 2014
No. of Shareholders: n/a
No. of Employees: 367
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , ,
Exchange London Stock Exchange (AIM)
Shares in Issue 375,199,334
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CIR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CIR
Upcoming Events for CIR
Friday 5th June, 2020 Estimate
Circassia Pharmaceuticals PLC Annual Shareholders Meeting
Similar to CIR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.